NCT00684463

Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)

Study to Evaluate the Efficacy and Safety of Single IV Doses of Onicit® (Palonosetron) 0.25 mg in the Prevention of Acute and Delayed Nausea and Vomiting Associated With Moderate and Highly Emetogenic Chemotherapy in Colombia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of single IV doses of Onicit® (Palonosetron) 0.25 mg in the prevention of acute and delayed nausea and vomiting associated with moderate and highly emetogenic chemotherapy.

Conditions

• Neoplasms
• Nausea
• Vomiting

Interventions

Type	Name	Description
DRUG	Palonosetron	0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent.

Timeline

• Start date: 2007-04-11
• Primary completion: 2008-02-22
• Completion: 2008-02-22
• First posted: 2008-05-26
• Last updated: 2017-05-16